Our Vision
We were formed in 2014 by neuroscience researchers at the Swiss Federal Institute of Technology (EPFL). We are headquartered in Eindhoven, the Netherlands, with an office in Lausanne, Switzerland and a growing US team based in Boston, Massachusetts.
Bob Odell brings to ONWARD decades of leadership experience in the medical device industry. Prior to joining ONWARD, Bob was President and Chief Operating Officer of Cardiac Insight, Inc., a successful startup that introduced disruptive technology to the global marketplace. Prior to Cardiac Insight, he served as COO for Cardiac Science, a publicly traded manufacturer of Class II and Class III devices. Bob has held executive assignments in Operations, Engineering, Marketing, Business Development. Information Technology and General Management with such notables as GE Healthcare, Siemens Medical Solutions, Philips Medical Systems, Medtronic, and Analogic. The foundation for his career is a degree in electrical and computer engineering from Syracuse University.
Amori Fraser serves as the Finance Director at ONWARD Medical, leveraging over 18 years of experience in both finance and auditing. Prior to her current role, she worked as a Senior Manager at EY, specializing in financial reporting, regulatory compliance, financial analysis and internal controls serving multi-national listed groups. Amori's experience in auditing and finance enables her to drive efficient financial operations and support the company’s growth initiatives. Amori holds a BComHons degree in Accounting Sciences from the University of Pretoria and is a qualified Chartered Accountant (CA) with the South African Institute of Chartered Accountants (SAICA).
Lorenzo Fanti is a dual-qualified US and English attorney with nearly 15 years of experience specializing in pharmaceuticals and medtech. Prior to joining ONWARD Medical, Lorenzo served as worldwide Legal Head, Ophthalmology ad interim at Novartis Pharmaceuticals, and, prior to that, he was Country Legal Head for Chile ad interim for the Novartis group of companies. He has held various roles with increasing responsibility at Novartis, including in the Neuroscience franchise, where he contributed to the launch of innovative migraine treatments. Early in his career, he was a Trademark Paralegal with Sandoz, and he trained with Allen & Overy LLP in London. He holds an LL.B. from the University of Wales.
ONWARD Update Call – Q3 2024 Business Update and Year-To-Date Highlights Investor Webcast
November 26, 2024 14.00 CET / 08.00 EST
To join the webcast via Zoom, please register using this link.